Compass Pathways (NASDAQ:CMPS) Stock Price Up 6.5% – Here’s Why

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) traded up 6.5% during mid-day trading on Wednesday . The stock traded as high as $14.60 and last traded at $14.9580. Approximately 556,640 shares were traded during trading, a decline of 84% from the average session volume of 3,543,970 shares. The stock had previously closed at $14.04.

Key Stories Impacting Compass Pathways

Here are the key news stories impacting Compass Pathways this week:

• Positive Sentiment: Durable Phase 3 results strengthen the COMP360 case. New 52-week open-label Part C data from the COMP005 trial showed that an additional COMP360 dose extended treatment benefits for up to one year, supporting the potential for infrequent dosing two to four times annually. The results helped drive a rise in CMPS shares and reinforced expectations for a possible 2027 launch. Compass Pathways Phase 3 COMP005 52-week results
• Positive Sentiment: Provider-training initiatives advance commercial preparation. Compass selected Fluence and other grant recipients to develop post-approval U.S. healthcare-provider training for COMP360. Building clinician education and treatment-delivery capabilities could help support adoption if the therapy receives FDA approval. Compass Pathways provider-training grant recipients
• Positive Sentiment: Management’s scheduled appearances at the H.C. Wainwright and Morgan Stanley healthcare conferences could provide additional visibility into the clinical program, regulatory plans and potential commercialization timeline. Compass Pathways investor conferences
• Neutral Sentiment: Technical commentary identified a potential breakout above $15.40, with substantially higher price targets. These are market projections rather than fundamental developments and may add momentum but do not reduce clinical or regulatory risk. Compass Pathways technical forecast
• Neutral Sentiment: The reported September short-interest figure was zero shares, unchanged from zero previously, with a days-to-cover ratio of zero. The accompanying “NaN” percentage change indicates a data-quality issue, so the entry provides no reliable signal about short-selling pressure.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on CMPS shares. B. Riley Financial lifted their price objective on shares of Compass Pathways from $17.00 to $22.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. BTIG Research upped their target price on shares of Compass Pathways from $14.00 to $25.00 and gave the company a “buy” rating in a report on Tuesday, July 7th. HC Wainwright cut their target price on shares of Compass Pathways from $70.00 to $65.00 and set a “buy” rating for the company in a research note on Friday, August 7th. Raymond James Financial reiterated a “buy” rating on shares of Compass Pathways in a report on Friday, May 22nd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Compass Pathways in a research report on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $23.36.

Compass Pathways Stock Performance

The company has a debt-to-equity ratio of 0.60, a current ratio of 1.30 and a quick ratio of 1.30. The stock’s 50-day simple moving average is $13.11 and its 200 day simple moving average is $10.54. The stock has a market capitalization of $1.97 billion, a P/E ratio of -3.08 and a beta of 2.54.

Compass Pathways (NASDAQ:CMPS) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($1.88) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($1.49). Research analysts expect that Compass Pathways PLC Sponsored ADR will post -1.26 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of CMPS. Royal Bank of Canada boosted its holdings in shares of Compass Pathways by 49.8% during the first quarter. Royal Bank of Canada now owns 89,446 shares of the company’s stock worth $256,000 after acquiring an additional 29,733 shares during the period. Acadian Asset Management LLC increased its stake in shares of Compass Pathways by 42.0% during the first quarter. Acadian Asset Management LLC now owns 240,591 shares of the company’s stock worth $686,000 after purchasing an additional 71,112 shares during the period. Nantahala Capital Management LLC increased its stake in shares of Compass Pathways by 47.7% during the second quarter. Nantahala Capital Management LLC now owns 4,179,930 shares of the company’s stock worth $11,704,000 after purchasing an additional 1,350,698 shares during the period. Balyasny Asset Management L.P. lifted its holdings in Compass Pathways by 38.0% during the 2nd quarter. Balyasny Asset Management L.P. now owns 854,840 shares of the company’s stock worth $2,394,000 after purchasing an additional 235,345 shares during the last quarter. Finally, Northeast Financial Consultants Inc acquired a new stake in Compass Pathways during the 2nd quarter worth approximately $59,000. 46.19% of the stock is owned by institutional investors.

Compass Pathways Company Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.